Background
A significant share of the cost of cancer care is concentrated in the end-of-life period. Although quality measures of aggressive treatment may guide optimal care during this timeframe, little is known as to whether these metrics affect costs of care.
Methods
We used population data to identify a cohort of patients who died of cancer in Ontario, Canada (2005 to 2009). Individuals were categorized as having received aggressive end-of-life care or not, according to quality measures related to acute institutional care or chemotherapy administration in the end-of-life period. Costs (2009 $CAN) were collected over the last month of life by linking health system administrative databases. Multivariable quantile regression was used to identify predictors of increased costs.
Results
Among 107,253 patients, the mean per patient cost over the final month was $18,131 for patients receiving aggressive care and $12,678 for patients receiving non-aggressive care (p<0.0001). Patients who received chemotherapy in the last 2 weeks of life also sustained higher costs compared to those who did not (p<0.0001). For individuals receiving end-of-life care in the highest cost quintile, early and repeated palliative care consultation was associated with reduced mean per patient costs. On multivariable analysis, chemotherapy in the 2 weeks of life remained predictive of increased costs (median increase $536; p<0.0001) whereas access to palliation remained predictive for lower costs (median decrease $418; p<0.0001).
Conclusions
Cancer patients who receive aggressive end-of-life care incur 43% higher costs than those managed non-aggressively. Palliative consultation may partially offset these costs and offer resultant savings.